EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series

Andrew Kolker iD

JCEM Case Reports · 03.09.2026 · 4 (10)

DOI: 10.1210/jcemcr/luag284 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 17.09.2026. Verfasst von Andrew Kolker. Beteiligte Einrichtung: Department of General Ophthalmology, Eye Doctors of Washington, Washington, D.C. 20036, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are increasingly prescribed for obesity and type 2 diabetes, but eyelid gland pathology has not previously been reported with these agents. We describe what we believe to be the first reported case series of 2 patients who developed multiple simultaneous internal hordeola after starting tirzepatide, a dual GLP-1/GIP receptor agonist. Patient 1, a 44-year-old woman, developed 6 simultaneous hordeola 4 weeks after dose escalation, 5 of which progressed to chalazia; lesions lessened after tirzepatide discontinuation and worsened upon rechallenge, a positive rechallenge providing strong evidence of causality. Patient 2, a 73-year-old woman with mild pre-existing blepharitis, developed 6 simultaneous hordeola 10 weeks after initiation of her 5 mg dose, 2 of which progressed to chalazia. Both patients lacked classic infectious blepharitis signs despite active lesions, supporting a sterile, obstructive meibomian gland process rather than infection, though both found the recurrences bothersome. These cases suggest a possible, previously undescribed association between tirzepatide and simultaneous or recurrent meibomian gland obstruction. Clinicians should be aware of this potential adverse eyelid effect and pursue conservative ophthalmic management before considering medication changes.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistschalazionhordeolummeibomian gland dysfunctionocular adverse effectstirzepatide

Autor:innen und Institutionen

  • Department of General Ophthalmology, Eye Doctors of Washington, Washington, D.C. 20036, USA.

ORCID-Profile: Andrew Kolker

Zitieren

APA

Kolker, A. (2026). Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series. JCEM Case Reports, 4(10). https://doi.org/10.1210/jcemcr/luag284

Vancouver

Kolker A. Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series. JCEM Case Reports. 2026;4(10). doi:10.1210/jcemcr/luag284

BibTeX
@article{Kolker2026,
  author = {Kolker, Andrew},
  title = {Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {10},
  doi = {10.1210/jcemcr/luag284}
}
Kostenlos starten →